Bio-Rad实验室 BIO 深 沪
已收盘 08-21 16:00:00 美东时间
380.03
+3.570
+0.95%
华盛通- 最 高385.92
- 今 开385.80
- 成交量 34.12万股
- 最 低 373.4697
- 昨 收 376.46
- 总市值 101.61亿
- 52周最高 385.92
- 市盈率 静 13.64
- 换手率 1.28%
- 52周最低 236.73
- 委 比 71.43%
- 总股本 2673.82万
- 历史最高 832.70
- 量 比 1.43
- 振 幅 3.31%
- 历史最低 84.02
- 每 手 1
- 风险率 23.68%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | AMD、Arista Networks、Booking 、加特纳、Pinterest、科力斯、Wayfair等获多家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Precigen"买入"评级，目标价从14美元升至18美元；HC Wainwright & Co.：维持Sophia Genetics"买入"评级，目标价从12美元升至14美元
08-06 11:36
财报速睇 | Bio-Rad实验室 2026财年Q2营收6.51亿美元，同比下降0.2%；归母净利润3.71亿美元，同比增长16.7%
华盛资讯8月5日讯，Bio-Rad实验室公布2026财年Q2业绩，公司Q2营收6.51亿美元，同比下降0.2%，归母净利润3.71亿美元，同比增长16.7%。
08-05 07:05
Bio-Rad Starts Restructuring Plan To Enhance Operating Performance; Restructuring Plan Includes Job Cuts, Function Consolidation, And Facility Closures Worldwide; Expects Pre-Tax Charges Of ~$80M - $90M; Restructuring Program Anticipated To Be Completed By End Of FY27
https://www.sec.gov/ix?doc=/Archives/edgar/data/12208/000001220826000046/bio-20260731.htm
08-05 05:15
财报速睇 | Bio-Rad实验室 2026财年Q2营收6.51亿美元，同比下降0.2%；归母净利润3.71亿美元，同比增长16.7%
华盛资讯8月5日讯，Bio-Rad实验室公布2026财年Q2业绩，公司Q2营收6.51亿美元，同比下降0.2%，归母净利润3.71亿美元，同比增长16.7%。
08-05 04:34
Bio-Rad Laboratories Lowers FY2026 Sales Guidance of $2.506B-$2.596B vs $2.567B Est
Bio-Rad Laboratories (NYSE:BIO) lowers FY2026 sales outlook from $2.506 billion-$2.596 billion to $2.506 billion-$2.596 billion vs $2.567 billion estimate.
08-05 04:24
Longleaf Partners Fund exits BIO
Longleaf Partners Fund underperformed with a return of 3.87% in Q2, as compared to the S&P 500's 15.20% gain and the Russell 1000 Value Index's 13.87% advance. The fund initiated one new position in a...
07-13 22:35
Bio-Rad估值达47倍还是Charles River处于调整阶段 2026年更值得买入的研究类股票
本次分析针对伯乐实验室（BIO）、查尔斯河实验室（CRL）两家生物实验室企业的估值与基本面表现展开对比研判，为不同投资偏好的标的选择提供参考。 核心关键数据如下...
06-23 06:23
Favorable Head-to-Head Data on iMDx’s GraftAssure with Competing NGS Assay Published in Clinical Chemistry
Insight Molecular Diagnostics Inc. announced the publication of a study in *Clinical Chemistry* comparing its GraftAssure™ test to a leading next-generation sequencing (NGS)-based assay for detecting donor-derived cell-free DNA (dd-cfDNA) in kidney transplant recipients. The study found 99.2% agreement between the two methods at the 0.5% clinical threshold, demonstrating their interchangeability. GraftAssure™ showed superior analytical sensitivit...
06-16 20:05
Kinaxis在拉斯维加斯Kinexions大会上揭晓2026年度客户大奖
全球供应链规划与协调领导者Kinaxis近日在拉斯维加斯举办的Kinexions北美大会上揭晓了其2026年度客户大奖获奖名单。这项已进入第八个年头的年度盛...
06-04 20:58
